Abstract | Clinicians who treat patients with stroke need to be aware of several single-gene disorders that have ischemic stroke as a major feature, including sickle cell disease, Fabry disease, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, and retinal vasculopathy with cerebral leukodystrophy. The reported genome-wide association studies of ischemic stroke and several related phenotypes (for example, ischemic white matter disease) have shown that no single common genetic variant imparts major risk. Larger studies with samples numbering in the thousands are ongoing to identify common variants with smaller effects on risk. Pharmacogenomic studies have uncovered genetic determinants of response to warfarin, statins and clopidogrel. Despite increasing knowledge of stroke genetics, incorporating this new knowledge into clinical practice remains a challenge. The goals of this article are to review common single-gene disorders relevant to ischemic stroke, summarize the status of candidate gene and genome-wide studies aimed at discovering genetic stroke risk factors, and to briefly discuss pharmacogenomics related to stroke treatment.
Introduction
Stroke is a leading cause of death and a major cause of acquired disability in adults. 1 In the USA, 795,000 strokes occur every year, of which 610,000 are first-ever (incident) strokes. The incidence of stroke has steadily increased despite proven strategies to reduce the risk of this disease. Ischemic stroke represents at least 80% of all strokes.
Traditional factors that increase the risk of ischemic stroke-such as hypertension, atrial fibrillation, and cigarette smoking-are well-known. Many of these traditional risk factors are modifiable or avoidable. Evidence from twin, case-control and cohort studies of familial aggregation of stroke risk indicate that stroke may be the result of shared genetic and environmental factors. 2 Genetic risk factors are often considered not to be modifi able; however, knowledge of genetic risk factors can provide insights into pathophysiological pathways and targets for drug therapy. The classic example of risk genes leading to therapeutic targets is familial hypercholesterolemia. 3 Thus, a public health impetus exists for defining genetic stroke risk (as exemplified by several initiatives to understand the underlying genetics of stroke; Boxes 1 and 2). Furthermore, the modern human in the industrialized world does not live in a state of nature, but rather in an ecosystem that includes routine exposure to medications (for example, statins, antihypertensive agents, and platelet antiaggregants). These exposures may modify genetic risk differently from traditional (known) risk factors. Means of defining inherited risk of stroke for this population include the study of pharmacogenomics.
The aims of this review are to summarize the clinical genetics of single-gene disorders that can lead to ische mic stroke, to review the progress in and prospects for solving the complex genetics of sporadic ischemic stroke, and to briefly discuss pharmacogenomics in the context of care of patients with stroke.
Single-gene disorders
In general, single-gene disorders are individually rare; however, collectively they represent important clinical conditions. Some single-gene disorders have specific treatments and, in many instances, conventional treatments may be ineffective or harmful. Understanding the pathophysiology of these single-gene disorders that can lead to stroke may provide insights into the mechanisms that underlie the more-common ischemic stroke.
CADASIL
The phenotypic manifestations of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) typically begin with migraine headache followed by ischemic stroke in the deep gray structures and subcortical white matter, and cognitive decline, ending in frank dementia. Apathy is evident in approximately two-fifths of patients with CADASIL, and further increases their disability.
Delta/Serrate/LAG-2 (DSL) ligand-binding domain, EGF 10-11, which can disrupt Notch 3 receptor function. 5 Individuals with mutations in the DSL-binding domain demonstrate a clinical-radiological dissociation with greater preservation of cognitive performance (despite a greater burden of white matter involvement on imaging) than patients with other pathogenic mutations.
Genetic testing for common NOTCH3 mutations that lead to CADASIL is available clinically, although skin biopsy remains a practical alternative for securing the diagnosis. A retrospective study of European patients with CADASIL demonstrated broad genetic heterogeneity with 34 different pathogenic mutations among 131 patients, but every case had diagnostic granular osmiophilic material on skin biopsy. 6 Biopsy of the skin for CADASIL diagnosis should include the border zone between the deep dermis and upper subcutis. An immuno staining technique directed at EGF repeats [17] [18] [19] [20] [21] in NOTCH3 has been developed that may improve the yield of a diagnostic skin biopsy. 7 In addition to skin biopsy, other nonmolecular tests can assist in the screening and diagnosis of this genetic disorder. MRI is essential to screen for both overt disease 8 The arteriopathy manifests by lacunes characterized as small subcortical hypointense lesions on T1-weighted imaging and by microbleeds characterized by signal dropout on T2-weighted gradient-echo sequences. Increases in smallvessel strokes, microbleeds and ventricular size correlate with cognitive decline. 9 In summary, CADASIL is a rare but devastating cerebro vascular disorder that provides an opportu nity to understand the mechanisms underlying other types of small-vessel arteriopathies, vascular dementia, and the relationship between migraine and stroke. The most common causal mutations for CADASIL occur in a gene coding for a cell-surface receptor (NOTCH3) that is widely expressed on vascular smooth-muscle cells. Investigators using animal models of CADASIL are characterizing the mechanisms in CADASIL and, just as importantly, in related phenotypes.
CARASIL
Individuals with cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalo pathy (CARASIL) typically have alopecia beginning in the second decade, spondylosis in their second and third decades, ischemic cerebrovascular disease in their third decade, and dementia in their third through fifth decades. Mutations in the HtrA serine peptidase 1 (HTRA1) gene were identified as the cause of CARASIL through linkage analysis. 10 Patients with HTRA1 mutations have protein products that tend to be incapable of repressing signaling by the transforming growth factor β protein family. CARASIL was initially described in indivi duals of Asian descent, but a European pedigree was described in 2010.
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Fabry disease Fabry disease is caused by mutations in the gene that codes for the α-galactosidase A (GLA) enzyme. Phenotypically, cerebrovascular manifestations of Fabry disease include premature stroke, dolichoectasia, and white matter hyperintensities. 12 In more than half of male and one-third of female cases of Fabry disease, stroke occurs before the condition is diagnosed. 13 Stroke remains the leading cause of death in Fabry disease.
5-year data from the Fabry Outcome Survey showed that GLA enzyme replacement led to decreased left ventricular mass and increase in medial fractional shortening, among other cardiac parameters.
14 Enzyme replacement also significantly reduced pain and improved quality of life. The influence of GLA replacement on stroke and other cerebrovascular manifestations of Fabry disease are not yet known.
The incidence of Fabry disease in patients with stroke varies across different study populations. A German study found Fabry disease in 4.9% of young men with cryptogenic ischemic stroke. 15 An epidemiological study in the Box 1 | Prospects in gene discovery in ischemic stroke
Once a region of the genome has been linked with stroke, using either genomewide linkage or genome-wide association approaches, the size of the interval is typically several hundred thousand bp. At this stage, dozens of genes may emerge (obvious and non-obvious candidates) that would be targets of interrogation. The approaches to enhancing the resolution of the genomic region include both dense single nucleotide polymorphism (SNP) mapping (using available SNP resources found in dbSNP, 86 HapMap 87 and 1000 Genomes 88 databases) and targeted resequencing of either coding regions (exons) or the entire interval (introns, exons, and intergenic regions). Massively parallel sequencing is becoming feasible on a genome-wide scale and has been used with some success in novel gene discovery for both autosomal and recessive rare disorders, clinical diagnosis of conditions such as primary ciliary dyskinesia, and molecular diagnosis of clinically recognizable conditions like Charcot-Marie-Tooth disease. 89 Massively parallel sequencing is now being applied to ischemic stroke as part of the Exome Sequencing Project (funded by the US National Heart, Lung and Blood Institute). The challenge will be to decipher which gene variants are benign and which are pathogenic in stroke. Strategies include filtering on function and frequency, ranking on conservation across species, and predicting the degree to which variants would alter protein structure and function.
Baltimore-Washington area in the USA observed Fabry disease in only 0.18% of all ischemic and 0.65% of cryptogenic strokes. 16 A Portuguese study found missense GLA mutations in 2.4% (95% CI 1.3-4.1%) of all consecutive patients aged 18-55 years with first-ever stroke of any type. 17 In a Belgian registry of patients aged 18-60 years presenting to neurologists with stroke, unexplained white matter lesions or vertebrobasilar dolicho ectasia, Fabry disease probably had a role in 1% of cases. 18 More studies are needed to better understand which cerebrovascular patient populations should be screened for Fabry disease.
Retinal vasculopathy with cerebral leukodystrophy
Retinal vasculopathy with cerebral leukodystrophy (RVCL) is caused by mutations in the TREX1 (3' repair exo nuclease 1) gene, typically in the c-terminal domain, which leads to loss of perinuclear localization of the cata lytically active TREX1 protein. 19 This condition has had several alternative disease designations, including cerebro retinal vasculopathy syndrome, hereditary vascular retinopathy, and HERNS (hereditary endotheliopathy, retinopathy, nephropathy, and stroke). Patients typically present in their 4 th decade with vision and memory loss, seizures, hemiparesis, and dysarthria. Death ensues within 5-10 years of presentation of initial symptoms. Brain imaging can reveal a tumefactive contrastenhancing white matter lesion that can regress in size over several months. 20 Lesions on MRI scans can be mistaken for multiple sclerosis. Retinal findings can include neovascularization of the optic disc, retinal hemor rhages, and macular edema. Anecdotally, intravitreal bevacizumab seems to be an effective treatment for the proliferative retinopathy associated with this disease. 21 Sickle cell disease Sickle cell disease, historically the first molecular disease to be described, is a condition that results from the substitution of valine for glutamic acid at position 6 of the β chain of hemoglobin (encoded by HBB). The mutation leads to aggregation of abnormal hemoglobin and changes in the shape and rheology of red blood cells. In addition to cerebrovascular complications, patients with sickle cell disease have hemolytic anemia, mild jaundice, and vaso-occlusive crises causing attacks of pain involving the chest, back and extremities.
The earliest description of symptoms consistent with sickle cell disease dates to 1670, with more-definitive descriptions emerging in the early 20 th century. 22 Genetic analysis supports multiple spontaneous mutations rather than a single founder effect. Haplotype analyses have identified at least four separate mutation events arising in Africa and Asia Minor or India. 23 In areas where malaria is endemic, enhanced survival in malaria outbreaks may have provided selective pressure favoring the presence of a single variant of the HBB gene. 22 Epidemiological data suggest that the spread of the disease across the Mediterranean basin, into Southern Europe and to the Americas is inextricably linked to slavery and the largescale forced translocation of populations from Africa and the Arabian penninsula. 24, 25 Sickle cell disease increases the risk of stroke 200-fold to 400-fold. Longitudinal cohort data from the late 1970s through the 1980s show a peak in the incidence of stroke between ages 2 years and 5 years. 26 Approximately onequarter of patients had stroke by age 45 years. Before age 20 years, most strokes in patients with sickle cell disease are ischemic, but beyond this age most strokes are hemorrhagic. Sickle cell disease can cause a cerebral vasculopathy characterized by proximal intracranial ar terial stenoses, often leading to a moyamoya pattern.
Although sickle cell disease is a paradigmatic singlegene recessive disorder, it is phenotypically complex. The clinical course of sickle cell disease ranges from early childhood mortality to a virtually asymptomatic condition. Evidence suggests that stroke risk differs among individuals with this condition. Overt stroke affects 25% of individuals with sickle cell disease by middle age. 26 The Stroke Prevention Trial in Sickle Cell Anemia (STOP) screened around 2,000 patients with sickle cell disease, and found that around 9% had a high-risk profile, as defined by transcranial Doppler ultrasonography (timeaveraged maximal mean blood flow velocities >200 cm/s in either the internal carotid or middle cerebral arteries on either side). Long-term follow-up showed that persistently elevated transcranial Doppler ultrasonography velocities reflected continually elevated risk of stroke. 27 Modifier genes and environmental factors may interact to determine the susceptibility to stroke among individuals with sickle cell disease; however, these modifiers remain incompletely characterized. Using Bayesian networks, Sebastiani et al. 28 analyzed single nucleotide polymorphisms (SNPs) from 80 candidate genes in 1,398 individuals with sickle cell disease. 25 SNPs from 11 genes and four clinical factors related to hemoglobin status (such as total hemoglobin concentration and percentage fetal hemoglobin) interacted to modulate the risk of stroke. 28 In a validation cohort, the model predicted the stroke status with 100% sensitivity and 98% specificity, for an overall pre dictive accuracy of 98%. Other research sug gests that vari ous genetic factors might differentially influence
Box 2 | Initiatives in stroke genetics research
The US National Institute of Neurological Disorders and Stroke is funding an ongoing ischemic stroke genetics consortium known as the Stroke Genetics Network (SiGN) . 90 This consortium is structured as a series of Genetic Research Centers (GRC) organized around a Data Coordinating Center. The GRCs contribute DNA samples for centralized genome-wide genotyping or data when such genotypic information is already available. The original Institute goal is to aggregate around 6,000 ischemic stroke cases. Most samples were collected under previous protocols, including hospital-based case series, population-based cross-sectional studies, and longitudinal cohort studies. A key goal is to have all stroke cases gathered under diverse protocols phenotyped uniformly. SiGN uses the Causative Classification of Stroke (CCS) system for subtyping ischemic stroke. 91 Physician data abstractors enter pertinent clinical and diagnostic testing information into web-based case report forms, and subtyping is then automatically generated using a computerized algorithm. The CCS has web-based training and certification modules. As of 23
rd March 2011, a total of 5,287 cases have been subtyped using this system. A random sample of charts is readjudicated by a central committee of vascular neurologists to assess agreement rates. SiGN will create a permanent global scientific resource by contributing to the Database of Genotype and Phenotype (dbGAP). 92 large-vessel and small-vessel cerebrovascular manifestations. 29 Parsing of genetic modifiers of stroke risk in mono genic diseases, such as sickle cell disease, may pro vide important insights into genetic determinants of common ischemic stroke and stroke subtypes.
Complex genetics of ischemic stroke
Evidence for heritability in ischemic stroke extends beyond the rare single-gene disorders discussed above. Stroke tends to run in families, suggesting that genetic factors influence risk. The Framingham study found that when a parent had a history of stroke before age 65 years, the risk of stroke in the offspring was increased 2.79-fold (95% CI 1.68-4.66). 30 A positive parental history for ischemic stroke before the age of 65 years translated to an increased risk of ischemic stroke among the children (odds ratio [OR] 3.15; 95% CI 1.69-5.88; P <0.001). Other investigators have found that early-onset stroke (stroke in patients aged <50 years) seems to be more herit able than late-onset stroke. [31] [32] [33] Candidate gene studies Initial studies of stroke risk focused on selective variants in candidate genes that were thought to be involved in biological pathways related to stroke. Studied candidate genes have included those associated with diverse pathologies including atherosclerosis, thrombosis, homocysteine metabolism, and hypertension. Early studies were plagued by methodological limitations, such as small sample size, potential for population stratification, and lack of replication in the study design. Heterogeneity of the ischemic stroke phenotype was commonly ignored and, when considered, was not approached in a standardized or reliable manner. 34 As a historical marker of the state of the field, Dichgans and Markus 35 in 2005 proposed standard criteria for ischemic stroke genetics to facilitate study replication and meta-analysis. The criteria called for rigorous phenotyping, including subclassification by presumed etiology, realistic sample sizes, prespecification of hypotheses to be tested, and independent replication of the findings.
With recognition of the complexity of the genetic basis of ischemic stroke and the probable modest effect of any one variant, these small single-stage studies evolved into large studies 36 and multistage studies. 37 Eventually, metaana lytical techniques were applied to published candidate gene studies 38 and to coordinated genotyping efforts involv ing teams of investigators. 39 Results of these efforts have been mixed. In individuals of European descent (the most studied population), associations with modest effect (OR <1.5) have been observed for common variants in the genes for coagulation factor V, methylenetetra hydrofolate reductase (MTFHR), prothrombin, and angiotensinconverting enzyme. 38 A meta-analysis of people of nonEuropean descent (mainly Chinese, Japanese and Korean indivi duals) produced similar results. 40 Though considerably smaller in size than studies of older adults, a meta-analysis of early-onset, adult ischemic stroke (aged 18-50 years) replicated associations observed with va riants in MTFHR and apolipoprotein E (APOE). 41 One of the great limitations of candidate gene studies is that any given genetic variant has a low pre-test pr obability of being truly associated with a phenotype. Candi date gene studies also presuppose more understanding about pathophysiology than is usually the case. Hav ing not found any single genetic variant or set of variants in a single gene with major effect, investigators migrated to hypothesis-neutral (agnostic) approaches, such as con ducting genome-wide linkage and genome-wide associ ation studies (GWASs).
Genome-wide studies Genome-wide linkage studies utilize family structure and large numbers of tagging SNPs to track the inheritance of stroke risk with the transmission of the SNP alleles. Although genome-wide linkage studies have the ability to detect single risk loci with relatively large effect, success has been limited. Early findings of a linkage between stroke and SNPs in PDE4D (encoding cAMP-specific 3',5'-cyclic phosphodiesterase 4D) 42 and ALOX5AP (encoding arachidonate 5-lipoxygenase-activating protein) 43 could not be replicated consistently. 44, 45 This incon sistent replica tion could be due, in part, to a limited num ber and low frequency in the population of genes of large effect for stroke, as well as difficulty in procuring stroke family materials that would be required for re plication of the previous findings.
GWAS approaches have been used in the past few years to characterize large samples of stroke cases and controls on the basis of screening for massive numbers of SNPs distributed throughout the genome to detect common variants with modest effects on stroke risk. Many groups have confirmed an association between SNPs in the chromosome 9p21 region and coronary athero sclerotic heart disease ( Figure 1) . [46] [47] [48] [49] On the basis of consistent evi dence for shared vascular risk factors between ischemic stroke and coronary atherosclerotic heart disease, the International Stroke Genetics Consortium (ISGC) investigated potential associations between ischemic stroke and variants in the 9p21 locus. A pooled analysis demonstrated that six SNPs were associated with athero sclerotic stroke indepen dently of demographic variables, coronary atherosclerotic heart disease, myocardial infarction, and other vascular risk factors. 50 The SNP that showed the greatest statistical significance in its association with ischemic stroke (rs1537378-C) had a pooled OR of 1.21. This risk locus seems to be acting directly on stroke risk and not through risk of myo cardial infarction, which could lead to cardio embolism. A locus on chromosome 4q25 adjacent to the transcription factor gene PITX2 (pituitary homeobox 2) was initially shown to be associated with atrial fibrillation, and was subsequently found to be associated with cardio embolic stroke in an analysis of 1,661 ischemic stroke cases and 10,815 controls. Two SNPs (rs2200733 and rs10033464) were associated with cardioembolic stroke in the discovery phase. 51 Somewhat unexpectedly, these SNPs were also associated with noncardioembolic stroke, leading to speculation that the noncardioembolic stroke group harbored a cryptic cardioembolic source, such as unrecognized intermittent atrial fibrillation. A separate analysis of over 4,000 cases of ischemic stroke did not confirm this reported association between non cardioembolic subtypes of ischemic stroke and SNPs in the 4q25 locus. Thus, the utility of genetic profiling to help classify individuals with cryptogenic stroke remains unresolved. 52 Another example of shared genetic risk of atrial fibrillation and ischemic stroke was observed for variation in the zinc finger homeobox protein 3 (ZFHX3) gene on chromosome 16q22. ZFHX3 encodes a protein that is involved in myogenic differentiation. A GWAS identified the rs7193343-T allele to be associated with atrial fibrillation (OR 1.21; P = 1.4 × 10 -10 ) and cardio embolic stroke (OR 1.22; P = 0.0002), with weaker evidence for an association with all ischemic stroke (OR 1.11; P = 5.4 × 10 -4 ). 53 The CHARGE (CoHorts for Aging Research in Genomic Epidemiology) consortium used a meta-analytical approach to perform a GWAS in four large cohorts involving 19,602 white individuals (in whom 1,544 incident strokes were recorded), with replication in a cohort of 2,430 black individuals (in whom 215 incident strokes occurred). 54 Independent replication of the association between a genetic locus on chromosome 12p13 and risk of stroke was demonstrated in the separate cohorts of black and white indivi duals. The finding was not, however, repli cated in an analysis of nearly 9,000 individuals with stroke (primarily drawn from case-control studies). 55 Survival bias is unlikely to explain the difference in findings. 56 In contrast to the original positive report, the failed replication study exhibited absence of heterogeneity among study participants. An additional possible explanation for the difference in results for locus 12p13 could be confounding by population stratification-which can arise when individuals with disease and controls have differences in allele frequencies primarily as a result of differences in ancestral origins-within populations of European descent.
A multistage study that used a GWAS for the first stage identified SNPs in the CELSR1 (cadherin EGF LAG sevenpass G-type receptor 1) gene as suscepti bility factors for ischemic stroke in Japanese individuals. 57 CELSR1 has not, however, been confirmed as a stroke risk gene in non-Japanese populations.
The regions of the human genome with the greatest evidence supporting association with ischemic stroke have largely been discovered in other conditions, such as coronary artery disease (chromosome 9p21) and atrial fibril lation (chromosome 4q25), with ischemic stroke confirmed to be secondarily associated. Much larger collections of stroke cases will be required to tease out true findings from false-positive findings of association and to augment identification of false negatives. 58 The Wellcome Trust Case Control Consortium-2 is a collabora tive venture to report on a larger than pre viously published GWAS that includes about 4,000 patients with ischemic stroke in the discovery phase. However, even this study is unlikely to be sizeable enough to identify small to mo derate risk alleles in stroke.
Mitochondrial studies
The syndrome of mitochondrial encephalopathy, lactic acidosis and stroke-like symptoms (MELAS) is a wellestablished, rare, maternally-inherited mitochondrial disorder. Classically, patients present with lesions that tend to cross vascular territories. Lesions are generally so-called metabolic strokes owing to cellular energy failure, but in rare instances strokes can be the result of cardioembolism from an associated cardiomyopathy.
Common variants in the mitochondrial genome may affect the risk of sporadic ischemic stroke (Table 1) . [59] [60] [61] [62] [63] A multicenter mitochondrial GWAS of ischemic stroke characterized 144 SNPs that were either directly genotyped or imputed. 59 A genetic risk score incorporating information from all the SNPs showed a statistically sig ni fi cant association with ischemic stroke with mini mal heterogeneity across study cohorts. How ever, no indivi dual variant reached statistical significance. The study, which involved 2,284 ischemic stroke cases, did not confirm a previously reported association with ha plogroups H1 and K. 60, 61 Familial aggregation of ischemic stroke Estimates of familial aggregation of ischemic stroke have varied by population and presumed etiology. Different assumptions of risk to relatives of stroke probands and This locus has been associated with a range of diverse vascular phenotypes, including symptomatic atherosclerotic conditions such as coronary artery disease (myocardial infarction), ischemic stroke (cerebral infarction) and peripheral artery disease, and arterial aneurysms including abdominal aortic aneurysm and intracranial cerebral aneurysm.
population prevalence suggest that the overall risk in siblings of a stroke proband is several-fold higher than that in the general population. Currently, the effects of known genetic loci contributing to stroke risk are substantially less than this expectation. Several factors could account for this discrepancy, including additional (undiscovered) genes, rare variants that are private to indivi duals and families, gene-gene and gene-environment interactions, regulatory effects through DNA splicing and/or DNA methylation, structural variation (rather than single nucleotide variation), and underlying heterogeneity owing to presumed stroke etiology (subtype). Emerging technologies that have yet to be fully applied to ischemic stroke relate to gene discovery, interactions, and regulatory or structural effects. On the other hand, much effort has been applied to better understand the underlying phenotypic heterogeneity in ischemic stroke (see below).
Several studies give insight into the relationship between phenotype and risk imparted by a positive family history of stroke. A study of 600 consecutive cases of ische mic stroke showed that family history was a risk factor for large-vessel stroke (OR 1.88), small-vessel stroke (OR 1.79) and cryptogenic ischemic stroke (OR 1.70). 64 A review of two population-based and three hospital-based family history studies found that a family history of stroke was least frequent for cardioembolic stroke and more frequent for stroke of non cardioembolic etiologies. 33 Importantly, comparison of findings from the population-based and hospital-based studies showed little evidence for inclusion bias.
Heritability (or heritability of stroke liability) seems to have a major role in stroke in younger patients. A study of 1,000 consecutive individuals with ischemic stroke recruited at St George's Hospital, London, UK found that individuals 65 years old or younger with a positive stroke family history had a greater risk of stroke than those without such a family history. 32 Two population-based studies from Oxfordshire, UK, found that family history of stroke was associated with younger stroke, the highest rates being observed in patients under 60 years (OR 1.73; 95% CI 1.02-2.91). 33 A trend towards increased risk of younger stroke was seen for large-vessel, small-vessel, cardio embolic and unknown subtypes of ischemic stroke. A population-based case-control study of young women with stroke in the Baltimore-Washington region found that the magnitude of aggregation of stroke increased with decreasing proband age. 31 Family history of stroke and risk of stroke in probands was greatest for women aged 15-24 years (OR 2.5; 95% CI 0.4-15) and declined with increasing proband age (OR 1.6; 95% CI 0.8-3.3 for ages 25-34 years and OR 1.5; 95% CI 1.1-1.9 for ages 35-49, P <0.0001).
Pharmacogenomics and ischemic stroke
Several proven medical therapies exist for preventing first or recurrent ischemic stroke, including anti platelet agents, anticoagulants, and antihypertensive agents. Pharmacogenomics, the study of how genetic variation can influence drug response, offers the potential to indivi dualize medical therapy for stroke and enable the use of specific drugs depending on an individual's genetic make-up.
Clopidogrel pharmacogenetics
The FDA has issued a warning that some people may res pond poorly to the antiplatelet agent clopidogrel, and that these poor responders might be identified by genetic testing. 65 Clopidogrel is a prodrug that requires metabolism by the cytochrome P450 complex to act on the P2Y 12 platelet receptor. CYP2C19 (cytochrome P450 family 2 subfamily C polypeptide 19) variants are associated with variable rates of metabolism of clopidogrel. Moreover, variations in ABCB1, which codes for a transmembrane transporter called multidrug resistance protein 1 (also known as P-glycoprotein 1), can lead to reduced concentration s of active drug.
Since the FDA warning in May 2010, substantially more information has become available that calls into question the clinical utility of gene testing for clopidogrel resistance. The TRITON-TIMI 38 Trial compared clopidogrel with another antiplatelet agent, prasugrel, in patients with acute coronary syndrome in whom percutaneous coronary intervention was planned. In the main study, prasugrel prevented more ischemic events, but caused more hemorrhages, than clopidogrel. In the pharmaco genetic analysis, patients with the ABCB1 3435TT genotype and patients with reduced function alleles of CYP2C19 were at increased risk of recurrent ischemic events on clopidogrel, but this was not the case for prasugrel. 66 In the PLATO (PLATlet inhibition and patient Outcomes) trial, which compared clopidogrel versus ticagrelor in patients with acute coronary syndromes, the pharmacogenetic study found ticagrelor to be more efficacious than clopidogrel, irrespective of polymorphisms in ABCB1 and CYP2C19. 67 An analysis of the CURE (Clopidogrel in Unstable angina to prevent Recurrent Events) and ACTIVE (Atrial fibril lation Clopidogrel Trial with Ibersartan for Prevention of Vascular Events) A trials showed that among patients with acute coronary syndrome or atrial fibrillation, the effect of clopidogrel as compared with placebo was consistent irrespective of ABCB1 and CYP2C19 genotypes. 68 In an analysis of the clopidogrel arm of the ACTIVE A trial, how ever, carriers of loss-of-function CYP2C19 alleles had a significant increase in risk of bleeding (P = 0.01), but when both treatment arms were analyzed and an inter action with genotypes was analyzed, loss-of-function carrier status was not signifi cantly associ ated with an interaction (P = 0.16). The analysis of the ACTIVE A trial provides an object lesson of the importance of pharmacogenet ic studies within a randomized clinical trial.
Warfarin pharmacogenetics
Warfarin at therapeutic doses reduces the risk of ischemic stroke by 60% in patients with atrial fibrillation. The dosage of warfarin needed to achieve thera peutic levels of anticoagulation varies considerably, and ge nomics may provide a way to tailor initiation of therapy, thereby minimiz ing underdosing and overdosing. The International Warfarin Pharmacogenetics Consortium created and validated a dosing algorithm using genetic testing of variants of CYP2C9 (cytochrome P450 2C9) and VKORC1 (vitamin K epoxide reductase complex subunit 1) in over 5,000 individuals (4,043 for construction of the dose algorithm and 1,009 for validation) of various ethnic groups. 69 The pharmaco genetic algorithm outperformed a clinical dosing algorithm and a fixed-dose algorithm in identify ing individuals requiring ≤21 mg per week and those requiring ≥49 mg per week. However, the study did not address whether the pharmacogenetic algorithm reduced the time to a stable international normalized ratio (INR), the number of INR measurements required or, more importantly, the number of thrombotic or hemor rhagic events. Although commercial testing is available for CYP2C9 and VKORC1, the absence of strong clinical evidence of utility has kept testing from being recommended for routine warfarin initiation. Diet, concomitant medications, and comorbidi ties contribute to the variability in warfarin responsiveness. Several multicenter randomized trials are underway to clarify the clinical significance of pharmacogenetic dosing of warfarin. 70 
Statin pharmacogenetics
Statins reduce the risk of ischemic stroke beyond what would be anticipated by their cholesterol-lowering effects; however, many patients cannot tolerate such therapy because of myalgias with or without myo pathy. A GWAS of definite or incipient myopathy identified variants in the SLCO1B1 gene, which encodes the hepatic drug transporter, solute carrier organic anion transporter family member 1B1. 71 Definite myopathy was defined as myalgias with creatine kinase level greater than 10 times the upper limit of normal. Patients treated with simvastatin had a 4.5-fold increase in the odds of myopathy per copy of the rs4149056-C (also known as SLCO1B1*5) allele; this allele results in a coding change of valine to alanine at amino acid 174 (Val174Ala, commonly known as T521C). A subsequent study of over 500 adults treated with various statin drugs found that the same allele was associated with a less severe phenotype (myalgias without substantial elevations in creatine kinase). 72 The risk of myopathy seemed greatest for carriers treated with simvastatin and negligible in those treated with pravastatin.
Summary
The era of cerebrovascular pharmacogenomics is now upon us. Despite heavy overlap with cardiovascular pharmacogenomics, the next few years will bring insights into specific genetic determinants of treatment effects analogous to the clopidogrel data, pharmaco dynamic effects analogous to the warfarin data, or adverse effects analogous to the statin data. Nearly 70 drugs include pharmacogenomic tests or biomarkers on their FDA label ing, and >10% of these drugs are used to treat or prevent cerebrovascular disease (Box 3). 73 The clinical application of these data is likely to precede that of genetic risk factor data.
Endophenotypes
Between risk factors and overt disease, intermediate states may serve as important indicators of cerebrovascular disease. These intermediate phenotypes, or endophenotypes, are associated with clinical cerebrovascular disease in the population, are independently and jointly heritable with stroke, and are present in individuals with and without stroke. The endophenotype concept originally arose in psychiatric genetics, 74 but is now broadly used in 92 to create a research resource broadly available to the scientific community. The stated aims of GARNET are to identify genetic variants that influence an individual's response to treatment; determine whether specific treatments are more or less effective defined by genotype; and develop and disseminate innovative methods for adding genomewide technologies to randomized clinical trials and interpreting the results in the context of a randomized treatment assignment. Specific attention is paid to identification of cross-study phenotypes for investigation, which have been organized around two main themes-women's health and vascular disease -given the focus of the three individual studies. GARNET provides genome-wide data on 2,667 individuals with ischemic stroke.
clinical genetics research. The myriad manifestations and underlying mechanisms of the ischemic stroke phenotype have driven investigators to look for tangible markers of cerebrovascular disease.
Carotid disease
Large-artery atherosclerosis is an important endophenotype for ischemic stroke. Etiologically, large-artery disease accounts for 20-30% of ischemic stroke in different populations. As mentioned above, rs1537378-C on chromosome 9p21 was associated with large-artery a therosclerosis-ischemic stroke independent of coronary disease in a large international meta-analysis.
Carotid disease represents an especially appealing intermediate phenotype because it can be measured and quantified noninvasively and inexpensively. Estimates of heritability for carotid atheroma vary. Both linkage and GWAS data from the Northern Manhattan Study and the Northern Manhattan Family Study supported genetic determinants of carotid atheroma (adjusted heritability 0.50; P <0.0001) and identified multiple linkage peaks in a study of individuals of Caribbean Hispanic origin. 75 One of the identified loci, on chromosome 14q32, has been previously implicated in other atherosclerotic disease. Genetic factors involved in the inflammatory milieu are also candidates that could influence the transition from asymptomatic to symptomatic state. 76 Carotid intima-media wall thickness (IMT) has been used as an intermediate phenotype for both ischemic stroke and coronary disease, although the optimal protocol and vessel for measuring carotid IMT is debated. Estimates for the heritability of carotid IMT range from 0.30 to 0.65 depending on the study population and the site of the carotid examined (common or internal). 77 IMT correlates with atherosclerosis, but may have both shared and distinct genetic determinants. A linkage study of IMT from the Northern Manhattan Study also found linkage on chromosome 14q very near the peak for carotid plaque. A GWAS analysis of subclinical atherosclerosis in the Framingham Offspring cohort included several measures of carotid IMT. 78 Although no SNP reached the threshold for GWAS-level significance, the top hit in a generalized estimating equation analysis was associated with internal carotid IMT with an adjusted P-value of 3.8 × 10
Small-vessel disease Leukoaraiosis refers to thinning of the white matter, best seen on MRI, and predominantly affects the periventricular and subcortical zones. Related terms include small-vessel disease and white matter disease. A metaanalysis of 46 longitudinal studies showed that leukoaraiosis is associated with an increased risk of stroke (hazard ratio [HR] 3.3; 95% CI 2.6-4.4), dementia (HR 1.9; 95% CI 1.3-2.8) and death (HR 2.0; 95% CI 1.6-2.7). 79 Variation in leukoaraiosis is estimated to be 55-80% heritable. [80] [81] [82] A meta-analysis of 46 studies of polymorphisms in 19 genes in 19,000 individuals found no association between a genetic polymorphism and leukoaraiosis. 83 Gene polymorphisms in APOE, angiotensinogen (AGT) and MTHFR were also investigated in 2,000 people, but no association with white matter hyperintensities was observed. Genome-wide linkage studies have also failed to identify genes accounting for the high heritability of this phenotype. 84 
MRI-defined brain infarcts
The CHARGE consortium performed a meta-analysis to identify loci associated with MRI-defined brain infarcts in 9,401 participants with no history of stroke or transient ischemic attack. 85 An infarct on MRI scanning was defined as an area of abnormal signal intensity in a vascular distribution that lacked mass effect and that was at least 3 mm in size. No association reached the preset threshold for genome-wide significance (P <5 × 10 -8 ).
Conclusions and future prospects
Ischemic stroke is a major public health problem with a heritable component to risk of the disease. Ischemic stroke figures prominently in the phenotypic expression of several single-gene disorders. Although these disorders are uncommon individually, they are essential to recognize because some, such as Fabry disease and sickle cell disease, have specific treatments. As in the case of sporadic stroke, the current wave of GWASs has yielded inconsistent results. Collaborative efforts to scale up these studies to overcome statistical-power failure are ongoing. Eventually, when reliable risk loci are identified, follow-up dense mapping and sequencing will need to be done. New discovery tools like exome sequencing (that is, sequencing of the entire collection of exons in an individual) and whole-genome sequencing are beginning to be applied to ischemic stroke.
Pharmacogenomics has yielded discovery of genetic variants that influence the responses to drugs commonly used in stroke prevention, including clopidogrel, warfarin, and statins. Incorporating these findings into clinical practice has been challenging. Warfarin pharmaco genomics illus trates an interesting case study in the utility of pharmaco genomics. As trials continue to clarify the clini cal utility of pharmacogenomics for predicting initial dosing of warfarin, direct thrombin inhibitors are emerging as reasonable alternative therapies. The sequence of drug approval followed by pharmacogenomic discovery will probably need to be reversed, or the two processes need to occur in parallel (so-called theragnostics, which combines therapeutics with diagnostics) if pharmacogenomic s is to become a practical clinical tool.
Next-generation sequencing of patient samples provides a detailed characterization of every individual's DNA sequence. Currently, the sequencing of coding regions (exons) provides the most likely correlation between DNA variation and functional outcome. Sequencing all coding regions of all genes in the human genome (the 'exome') can provide a comprehensive view of potential causal variants in genes contributing to disease risk, as well as a promising alternative method for characterization of response to pharmacological therapy. Currently, these next-generation sequencing methods are used primarily as discovery tools, rather than directly for personal ized genomic medicine. Exome sequencing of a large panel of individuals can generate accurate allele frequency information for many known disease risk and pharmacogenetic variants, leading to a more accurate picture of the distribution of these alleles in the population at large. The accumulated exome data will reveal novel variants, both rare and common, that may have a role in disease risk or therapeutic response. In the future, as genes and gene pathways are identified that contribute to stroke risk and response to treatment, a catalog of variants will be available to permit construction of genomic risk profiles (similar in context to a Framingham Risk Score). The cost of an exome sequence will be in the same range as for a current imaging diag nostic test (under US$1,000), but an exome sequence needs only to be generated once (although data may be accessed and utilized multiple times), whereas diagnostic tests may need to be ordered repeatedly. Thus, exome sequencing could provide information on DNA variation in the set of genes important for stroke diagnosis and treatment.
Review criteria
PubMed was searched to February 2011 using the terms "ischemic stroke", "genetics", "genomics", "sequencing", "cerebral infarction", "CADASIL", "CARASIL", "RVCL", "Fabry disease", "sickle cell disease", and "genome-wide association studies". The search was limited to full-length articles and short reports in the peer-reviewed medical literature in English. Reference lists of identified papers were also searched for further relevant articles.
